Drugmaker Shire makes $30bn offer for Illinois firm Baxalta

Adderall XR amphetamine maker Shire is looking to buy Baxalta for $30 billion, it has revealed.

The Illinois-based drugmaker Baxalta is involved in developing treatments for rare conditions.

The bid by Shire comes amid several mergers in the industry. On Monday, Shire agreed to buy Foresight Biotherapeutics for $300 million. Earlier in the year, Shire bought NPS Pharma for $5.2 billion. In 2014, AbbVie had made a failed $50 billion takeover bid of Shire. ﻿﻿